Leukemia, Lymphocytic Clinical Trial
Official title:
A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)
The primary objective of this study is to see if enzastaurin affects the pGSK3 beta level in B-cell chronic lymphocytic leukemia (B-CLL) cells.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00270049 -
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Completed |
NCT00313079 -
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Completed |
NCT00327678 -
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
|
Phase 3 | |
| Completed |
NCT00025662 -
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
|
Phase 2 | |
| Terminated |
NCT00306332 -
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
|
Phase 3 | |
| Recruiting |
NCT05254743 -
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Completed |
NCT00034684 -
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
|
Phase 1/Phase 2 | |
| Completed |
NCT00361140 -
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
|
Phase 4 | |
| Completed |
NCT00035022 -
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT01144793 -
Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias
|
N/A | |
| Active, not recruiting |
NCT00315419 -
Identifying Characteristics of Bone Marrow Failure Syndromes
|
N/A | |
| Active, not recruiting |
NCT03792256 -
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
|
Phase 1 |